Ovarian Hyperstimulation Syndrome Prevention Strategies: In Vitro Maturation

被引:30
作者
Huang, Jack Y. J. [1 ]
Chian, Ri-Cheng [2 ]
Tan, Seang Lin [2 ]
机构
[1] Weill Cornell Med Coll, Ronald O Perelman & Claudia Cohen Ctr Reprod Med, New York, NY 10021 USA
[2] McGill Univ, Dept Obstet & Gynecol, Montreal, PQ H3A 2T5, Canada
关键词
In vitro maturation; ovarian hyperstimulation; immature oocyte; INTRACYTOPLASMIC SPERM INJECTION; HUMAN CHORIONIC-GONADOTROPIN; BECKWITH-WIEDEMANN-SYNDROME; IMMATURE HUMAN OOCYTES; REGULARLY MENSTRUATING WOMEN; ENDOTHELIAL GROWTH-FACTOR; INVITRO FERTILIZATION; ASSISTED REPRODUCTION; POLYCYSTIC OVARIES; BLASTOCYST DEVELOPMENT;
D O I
10.1055/s-0030-1265680
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The only reliable way to eliminate the risk of ovarian hyperstimulation syndrome (OHSS) is complete avoidance of gonadotropin ovarian stimulation. It could be argued that in vitro maturation (IVM) of oocytes represents the most effective strategy to prevent OHSS. IVM has been an established treatment option in many centers worldwide for over a decade. The use of IVM and natural cycle in vitro fertilization (IVF) combined with IVM can result in clinical pregnancy rates that compare to those obtained with conventional IVF. The obstetric and perinatal outcomes of IVM pregnancies are similar to those conceived from stimulated IVF or spontaneous conceptions. To date, more than a thousand healthy infants have been born without an increase in fetal abnormalities. Although IVM may not replace standard IVF, it plays an increasingly important role in assisted reproductive technology, especially in the settings of high responders and those patients at risk of OHSS.
引用
收藏
页码:519 / 531
页数:13
相关论文
共 50 条
[21]   Pharmacotherapy of ovarian hyperstimulation syndrome [J].
Genazzani, Andrea Riccardo ;
Monteleone, Patrizia ;
Papini, Francesca ;
Artini, Paolo Giovanni .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (15) :2527-2534
[22]   CABERGOLINE IN PREVENTION AND TREATMENT OF OVARIAN HYPERSTIMULATION SYNDROME [J].
Dosedla, Erik ;
Gasparova, Petra ;
Ballova, Zuzana ;
Sitas, Martina ;
Turcsanyiova, Zuzana ;
Calda, Pavel .
AKTUALNI GYNEKOLOGIE A PORODNICTVI, 2023, 15 :49-54
[23]   In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction [J].
Siristatidis, Charalampos S. ;
Maheshwari, Abha ;
Vaidakis, Dennis ;
Bhattacharya, Siladitya .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (11)
[24]   Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment [J].
Navot, Daniel ;
Bergh, Paul A. ;
Laufer, Neri .
FERTILITY AND STERILITY, 2019, 112 (04) :E209-E221
[25]   In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction [J].
Siristatidis, Charalampos S. ;
Vrachnis, Nikos ;
Creatsa, Maria ;
Maheshwari, Abha ;
Bhattacharya, Siladitya .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10)
[26]   Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome [J].
Kwik, Michele ;
Maxwell, Elizabeth .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2016, 28 (04) :236-241
[27]   Ovarian hyperstimulation syndrome [J].
Le Gouez, A. ;
Naudin, B. ;
Grynberg, M. ;
Mercier, F. -J. .
ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2011, 30 (04) :353-362
[28]   Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome [J].
Youssef, Mohamed A. F. M. ;
Al-Inany, Hesham G. ;
Evers, Johannes L. H. ;
Aboulghar, Mohamed .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (02)
[29]   Guideline No. 315: Prevention of Ovarian Hyperstimulation Syndrome [J].
Corbett, Shannon ;
Shmorgun, Doron ;
Claman, Paul .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2023, 45 (07) :534-535
[30]   Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome [J].
Spitzer, Dietmar ;
Wogatzky, Johannes ;
Murtinger, Maximilian ;
Zech, Mathias H. ;
Haidbauer, Robert ;
Zech, Nicolas H. .
FERTILITY AND STERILITY, 2011, 95 (08) :2742-U405